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changes in gene expression patterns and epigeneticmarks. To better understand the link between gene expression andDNAmethylation,
we have profiled human somatic cells from different embryonic cell types (endoderm, mesoderm, and parthenogenetic germ cells)
and the iPSCs generated from them. We show that reprogramming is accompanied by extensive DNA methylation in CpG-poor
promoters, sparing CpG-rich promoters. Intriguingly, methylation in CpG-poor promoters occurred not only in downregulated genes,
but also in genes that are not expressed in the parental somatic cells or their respective iPSCs. These genes are predominantly tissue-
specific genes of other cell types from different lineages. Our results suggest a role of DNA methylation in the silencing of the somatic
cell identity by global nonspecific methylation of tissue-specific genes from all lineages, regardless of their expression in the parental
somatic cells.INTRODUCTION
Forced expression of transcription factors in human so-
matic cells allows the generation of induced pluripotent
stem cells (iPSCs) (Takahashi et al., 2007). These cells are
equivalent to inner-cell mass-derived embryonic stem cells
(ESCs) and hold a great promise for regenerative medicine
and cell replacement therapy. The way somatic cells transi-
tion to the pluripotent state is not yet fully elucidated. The
activation of the pluripotent state depends on the ability to
upregulate a set of pluripotency genes. Unraveling the way
by which pluripotent factors interact with the genome is
key to understanding cellular reprogramming (Plath and
Lowry, 2011). Although the thorough studies concerning
the action of the pluripotent factors illuminate some aspect
of the silencing of the somatic cell identity, the induction
of pluripotency gene targets by itself is insufficient to solely
explain the conversion of somatic cells into pluripotent
cells, and other cellular processes need to occur for the
erasure of the somatic cell identity.Methylation of cytosine
in the context of CpG dinucleotides in gene promoters has
been acknowledged for many years as a mechanism for
regulation of gene expression in mammalian cells (Cedar
and Bergman, 2009). Differential gene expression between
somatic cells and ESC cells has been shown to be governed
by methylation of gene promoters (Meissner et al., 2008).
The genomic landscape affects the location and level ofStem Cell RDNAmethylation by the content of the CpG dinucleotides
in a given genomic region. DNAmethylation density varies
in a CpG rich versus CpG poor regions (Hawkins et al.,
2010; Lister et al., 2011). Overall, gene promoters are gener-
ally characterized by a high content of CpG dinucleotide
(HCpG) known as well as CpG Islands, or by a low content
of CpG dinucleotide (LCpG). Given the complex interplay
between DNA methylation and gene expression, compre-
hensive correlation analysis can illuminate our under-
standing of the reprogramming process. Recent studies
that have focused on DNA methylation profiling of
different CpG regions during reprogramming, included
limited expression analysis, mainly in the form of prese-
lected genes sets with an a priori knowledge regarding their
mode of action (Nishino et al., 2011; Weber et al., 2007).
Other studies have focused on CpG regions from an oppo-
site direction, i.e., the methylation processes that occur
when pluripotent cells differentiate in culture (Brunner
et al., 2009; Xie et al., 2013). Here, we set out to investigate
the methylation and expression dynamics of somatic cells
representative of three different embryonic cell types
(mesoderm, endoderm, and teratoma cells derived from
parthenogenetic germ cells) and their respective iPSCs.
We thus aimed at deciphering the involvement of DNA
methylation in silencing the somatic cell identity in the
context of different somatic cells with distinct genetic
and epigenetic backgrounds.eports j Vol. 1 j 509–517 j December 17, 2013 j ª2013 The Authors 509
Figure 1. Expression Analysis of Somatic and Pluripotent Cell Lines
(A) Hierarchical clustering analysis based on mRNA expression. Somatic cells and their derived iPSCs are designated in dark/light matching
colors.
(B) Principal-component analysis (PCA) based on RNA expression levels across somatic and pluripotent cell samples. Coloring indicates
classification of samples into subgroups. Light brown and gray shades represent somatic and pluripotent cells, respectively.
(legend continued on next page)
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To study the status of DNA methylation during cellular re-
programming, we have analyzed the gene expression and
methylation profiles of somatic cells from three different
lineages, representative of different embryonic germ-
layers, and the iPSCs derived from them, as well as control
human ESCs. For mesoderm, we have chosen human fibro-
blasts and the iPSCs (Fib-iPSCs) generated from them (Pick
et al., 2009; Urbach et al., 2010). For endoderm, we have
used human pancreatic beta cells and beta-iPSCs (Bar-Nur
et al., 2011), and for the germline we have used human
parthenogenetic ovarian teratoma-derived cells and
parthenogenetic iPSCs (Pg-iPSCs) generated from them
(Stelzer et al., 2011). For each lineage, we have used
between two and three iPSC clones in all analyses. We
initially compared the somatic and pluripotent cells by
gene expressionmicroarrays. As expected, an unsupervised
hierarchical clustering separated the somatic and pluripo-
tent cells into two distinct groups (Figure 1A). Within the
somatic group, further separation was observed based on
the origin of the somatic cells; however, for the pluripotent
cells, this distinction was only seen in the Pg-iPSCs versus
other iPSCs, probably due to the lack of expression of
paternal imprinted genes in the parthenogenetic cells (Fig-
ure 1A). Further separation of somatic versus pluripotent
cells was observed following principal-component analysis
(PCA; Figure 1B) that placed all pluripotent cells in one
group while all somatic cell were clustered in a separate
group. As expected, pluripotent cells, although generated
from various origins, were clustered tightly together (Fig-
ure 1B). We then correlated each iPSC clone to the somatic
cell fromwhich it was derived (Figure 1C). This has allowed
us to generate four different groups of genes: (1) genes that
are upregulated following reprogramming (‘‘pluripotency
genes’’), (2) genes that are downregulated following reprog-
ramming (‘‘somatic genes’’), (3) genes that are not ex-
pressed in both cell types (‘‘nonexpressed genes’’), and (4)
genes that are expressed in both cells types (‘‘coexpressed
genes’’) (Figure 1C). This analysis shows that only a rela-
tively small subset of genes are differentially expressed be-
tween iPSCs and the somatic cells from which they are
derived (Figure 1C). Next, we looked at the overlap among
the three different somatic lineages within each of the four(C) Scatterplot of somatic and iPSC gene expression. x axis = fibrob
divided into four gene expression categories: (1) coexpressed genes
ripotency-specific genes (black, red, green, and blue, respectively).
(D) Gene overlap for the coexpressed genes, nonexpressed genes, an
(Beta), fibroblast (Fib), and parthenogenetic teratoma (Pg-Ter) lineag
(E) Gene expression of typical core pluripotency genes among the soma
(s) and pluripotent (p) cells; y axis = gene expression level. Parental or
color (dark/light hues). Horizontal black line represents an expressio
Stem Cell Rgene expression categories. Coexpressed and nonexpressed
genes show a high overlap (88% and 80%, respectively)
among the three groups (Figure 1D). Somatic-specific genes
show low overlap among the three groups (30%), which is
expected since each cell type represents a different embry-
onic lineage. Lastly, the expression levels of well-known
pluripotency related genes were significantly higher in all
the pluripotent cells compared to the somatic cells (Fig-
ure 1E). We then profiled the methylation status of the
cells. We have used Illumina’s Infinium Methylation 27
BeadChip Platform arrays that sample 27,578 CpG sites
in promoters regions covering about 15,000 genes in the
genome. Here, again, unsupervised hierarchical clustering
separated the somatic and pluripotent cells into two
distinct groups, with continued subdivision into smaller
groups based on the cell type (Figure 2A). Similar to the
above expression analysis, the PCA method was applied
and a clear distinction between pluripotent and somatic
cells was observed (Figure 2B). We next looked at the global
methylation levels in each cells type. The Illumina array
samples CpG across the genome and gives a b value for
methylation in each CpG, ranging between 0 and 1 (where
0 is not methylated and 1 is fully methylated). CpG that is
fully methylated (i.e., score of ‘‘1’’) is representative to the
sampled region. We divided the b values into three
categories: (1) hypomethylated (b between 0 and 0.3), (2)
hemimethylated (b between 0.3 and 0.6), and (3) hyperme-
thylated (b between 0.6 and 1). The Illumina platform
allows dividing the methylation of the genes into two
distinct groups: CpG island promoters (characterized by
HCpG content) and nonisland CpG promoters (character-
ized by LCpG content). The methylation patterns in the
somatic cells show that they are more methylated in the
LCpG and that CpG islands are overall notmethylated (Fig-
ure 2C). All the iPSCs showed higher b values than their
corresponding somatic cells and were similar to the levels
observed in ESCs (Figure 2C), thus corroborating previous
observations (Hawkins et al., 2010; Lister et al., 2011).
The higher methylation levels observed in iPSCs were pre-
dominantly located in LCpG, while the HCpG promoters
showed little change in methylation levels following re-
programming (p value < 0.0001 and p value = 0.61, respec-
tively; Figure 2C). Our analysis shows that most of the
genes having HCpG content show low levels oflast cell expression; y axis = Fib-iPSC expression. Transcripts were
, (2) nonexpressed genes, (3) somatic-specific genes, and (4) plu-
d somatic genes are presented in the Venn diagrams. The beta cell
es are represented by light green, light red, and purple, respectively.
tic and pluripotent cells. x axis = pluripotency genes for the somatic
igin cell line and their respective iPSCs are designated by a different
n threshold.
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Figure 2. DNA Methylation Analysis of Somatic and Pluripotent Cell Lines
(A) Hierarchical clustering analysis based on DNAmethylation. Somatic cells and their derived iPSCs are designated in dark/light matching
colors.
(B) PCA based on CpG methylation levels across somatic and pluripotent cell samples. Coloring indicates classification of samples into
subgroups. Light brown and gray shades represent somatic and pluripotent cells, respectively.
(C) Distribution of methylation scores across somatic and pluripotent cells. The three histograms represent the distribution of hyper-
methylated (>0.6), hemimethylated (0.3–0.6), and hypomethylated (<0.3) genes (red, blue, and green, respectively) for all island CpG and
nonisland CpG sites. p values = Fisher’s exact test.
(D) CpG site distance from transcription start site (TSS). The histogram shows the distribution of distance from the TSS for the CpG island
and nonisland CpG sites (orange and purple, respectively). y axis = distance from TSS in base pairs.
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gree of methylation. Overall, the methylation levels in
these gene promoters does not dramatically change
following reprogramming and they remain either hypo-512 Stem Cell Reports j Vol. 1 j 509–517 j December 17, 2013 j ª2013 Theor hypermethylated (Figure 2C). Our analysis also shows
that methylation is much more prominent following re-
programming than demethylation (Figure 2C). The distri-
bution of the distance of the CpG dinucleotides from theAuthors
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HCpG sites are located in 1,000 bp range from the TSS
(89% and 97%, respectively; Figure 2D), in accordance
with other studies that compared tissue-specific genes
and highly expressed housekeeping genes (characterized
by nonisland CpG and CpG islands, respectively) (Brenet
et al., 2011; Morita et al., 2012). In summary, our data
show that reprogramming is accompanied by massive
methylation of gene promoters that have a low number
of CpG dinucleotides, resembling the state in ESCs. This
de novo methylation occurred in all the iPSC clones,
regardless of the starting cell type or lineage.
We next sought to look at the correlation between the
methylation and expression levels of each somatic cell
and the iPSCs that were generated from it. We looked at
the methylation status for CpG island or nonisland CpG
promoters in the four expression groups that we generated
previously (Figure 1C). Although the overall methylation
proportions of HCpG genes provide a rather static picture
(Figure 2C), a certain fraction of the genes change their
methylation status following reprogramming (Figure 3A).
Plotting methylation versus expression revealed that
many upregulated pluripotency genes underwent pro-
moter demethylation following reprogramming, especially
those that are located in HCpG promoters, as the vast
majority of pluripotent genes are characterized by CpG
island promoters (Figure 3A). Concomitantly, the
somatic-specific gene group that is downregulated in iPSCs
underwent extensive de novo methylation in LCpG rather
than inHCpGpromoters (Figures 3A and 3B; Figures S1 and
S2 available online). Intriguingly, genes that are not
expressed in either somatic cells or iPSCs generated from
them showed a great increase in methylation in LCpG
promoters, regardless of the parental somatic cell type (Fig-
ure 3B; Figure S2). The nonexpressed gene groupwas signif-
icantly different from the coexpressed genes in the LCpG
category and also greatly differs from the nonexpressed
gene group in the HCpG category (Figures 3B; Figure S2).
This group of genes behaves in a similar fashion to the
somatic-specific gene group, which shows a similar de
novo methylation trend. This raised an interesting issue:
whywould genes that are not expressed by the somatic cells
undergo extensive de novo methylation? To address this
issue, we used the Amazonia database (http://amazonia.
transcriptome.eu/; Le Carrour et al., 2010), which shows
the expression levels of most human genes in hundreds
of human tissue samples representing the cell repertoire
of the human body. Analysis of the genes that are not ex-
pressed in any of the three somatic cell types or their respec-
tive iPSCs by the Amazonia database demonstrated that
they are tissue-specific genes, each representing a different
cell type (Figure 3C; Table S1) such as skin, intestine, blood,
bone marrow, testis, or brain. The differences in methyl-Stem Cell Ration between the somatic and the pluripotent cells were
highly significant for all cell-specific genes. A gene ontology
annotation analysis of these genes showed enrichment for
processes such as epidermal, keratinocyte, and epithelial
cell differentiation and developmental processes.DISCUSSION
DNA methylation is an epigenetic modification that plays
a pivotal role in the silencing of gene expression, such as
the silencing of imprinted genes or genes that reside in
the inactive X chromosome (Cedar and Bergman, 2009;
Weber et al., 2007). How the role of DNA methylation in
resetting the epigenome of somatic cells following reprog-
ramming to pluripotency is not yet fully understood. Since
reprogramming to pluripotency dictates the activation
and repression of a subset of genes, it is expected that
methylation will play major role in this process. Repres-
sion of lineage-specific genes that are not expressed in a
given somatic cell can be maintained due to the fact that
specific transcription factors are absent. This regulation
can then be augmented by DNA methylation executed
by de novo methylases. Our results, using three different
somatic cells and their iPSC progenies, corroborates previ-
ous observations that reprogramming is accompanied by a
wave of de novo methylation in iPSCs (Deng et al., 2009;
Doi et al., 2009; Lister et al., 2011; Nagae et al., 2011; Nish-
ino et al., 2011). Although the de novo methylase
DNMT3b is expressed only in the pluripotent cells (Fig-
ure 1E), the trajectory in which hypermethylation is
acquired can occur alongside gene repression, to precede
the regulatory repression, or to occur after the gene is
silenced. In addition, our work refines these observations
by analyzing the expression levels of the cells, showing
that this methylation occurs not only for the somatic-spe-
cific expressed genes, but also for many other nonex-
pressed genes.
Our results can be explained by the following model.
During reprogramming, the de novo DNA methyltrans-
ferases (DNMTs) methylates not only the promoters of
the somatic-specific genes that are undergoing reprogram-
ming, but also the promoters of most cell-specific genes,
even if they are not expressed in the somatic cell undergo-
ing reprogramming (Figure 4). This suggests that the
DNMTs cannot separate between the different tissue-
specific promoters of the cell undergoing reprogramming
and that gene silencing occurs in an indiscriminate mode
that does not distinguish between parental cells from
different lineages. For example, the gene CMTMC5 is ex-
pressed predominantly in ectodermal cells of the adult
brain; however, this gene undergoes de novo methylation
in iPSCs that are generated from mesoderm, endoderm,eports j Vol. 1 j 509–517 j December 17, 2013 j ª2013 The Authors 513
Figure 3. Analysis of Combined Expression and Methylation Data
(A) Expression versus methylation. For fibroblast versus fib-iPSCs, island CpG and nonisland CpG are presented separately. x axis =
expression ratio (log iPS cell expression  log somatic cell expression); y axis = methylation difference (iPS methylation  somatic cell
methylation). A positive value on the y and x axes reflects higher methylation or expression in iPSCs than in the parental somatic cells and
vice versa. Colors represent the four expression categories as in Figure 1B. Regression lines are presented for the somatic and pluripotent
gene categories (green and blue, respectively), and shaded gray boundaries represent confidence interval (CI). See also Figure S1.
(B) Comparison of DNA methylation of fibroblast and their respective iPS cell line. y axis = methylation difference based on fib-iPSCs values
minus fibroblast values. A positive value reflects higher methylation in iPSCs than in the parental somatic cells and vice versa. The box
plots illustrate the methylation difference for each expression category (Figure 1C) and for the CpG and nonisland CpG groups. Each panel
represents different cell origins (fibroblasts, beta cells, and parthenogenetic teratomas). p value = Student’s t test. See also Figure S2.
(C) Tissue-specific gene expression profile using the Amazonia database. The displayed genes, which are not expressed in the somatic (S)
and pluripotent (P) cells, become hypermethylated during reprogramming. mRNA expression and methylation values are presented in the
histograms. Left side = expression; right side = methylation. Center histogram: expression levels in various tissues and cells. GAPDH and
SALL4 serve as control for housekeeping and pluripotency genes, respectively. Black line = expression threshold; dotted black line =
threshold for hypermethylation and hypomethylation. See also Table S1.
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(Figure 3C). A different interpretation is that iPSCs undergo
extensive aberrant methylation in vitro (Lister et al., 2011).
However, the high concordance between methylation of
the tissue-specific genes among our iPSCs that are gener-
ated from distinct lineages suggests otherwise. If indeed
the methylation of tissue-specific genes represents an aber-
rant phenomenon, then we would not expect it to be514 Stem Cell Reports j Vol. 1 j 509–517 j December 17, 2013 j ª2013 Theconsistent across three diverse cell types and many inde-
pendent and different reprogramming experiments. In
addition, a recent study shows that keratinocytes repro-
gram much faster than fibroblasts because they are more
methylated than fibroblasts (Barrero et al., 2012). In this
case, the DNMTs may not need to methylate all the
tissue-specific gene promoters, thus enhancing reprogram-
ming efficiency.Authors
Figure 4. A Model that Illustrates the
Possible Silencing of the Somatic Cell
Identity following Reprogramming by
DNA Methylation
Following reprogramming, pluripotency-
related gene promoters undergo extensive
DNA demethylation regardless of the start-
ing somatic cell type. Somatic cell-specific
gene promoters undergo extensive methyl-
ation (illustrated by a fibroblast cells).
Other cell-specific gene promoters also un-
dergo extensive DNA methylation, as the
methylating enzymes cannot distinguish
between various somatic cell-specific pro-
moters, thus acting in a ‘‘blind fashion.’’
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Global Indiscriminate Methylation in Human iPSCsIn mouse ESCs, it was recently shown that the cells
are hypermethylated when grown with serum; however, a
switch to serum-free medium supplemented with
mitogen-activated protein/extracellular signal-regulated
kinase kinase (MEK) inhibitor or GSK3 inhibitor (2i me-
dium) results in genome-wide hypomethylated mouse
ESCs that resemble an earlier developmental ‘‘naı¨ve state’’
(Leitch et al., 2013). Human ESCs may represent a later
developmental stage than mouse ESCs, more similar to
the mouse epiblast stem cell stage (Tesar et al., 2007).
Human iPSCs resemble human ESCs, and thus the high de-
gree of methylation we observe in both cell types may
represent a depiction of their in vivo postimplantation
state, just before the cells start to acquire their somatic
cell identity. It will be interesting to examine the methyl-
ation status of naive human PSCs and see if they are rela-
tively hypomethylated (Hanna et al., 2010). Which
enzymes mediate the extensive de novo methylation dur-
ing reprogramming is yet to be determined. A recent
work shows that non-CpG methylation in PSCs is medi-
ated by DNMT3a and DNMT3b, as knocking down these
genes eliminated most of the non-CpGmethylation (Ziller
et al., 2011). It is likely that these enzymes are also respon-
sible for the de novo methylation we detect in iPSCs in
LCpG promoters as the expression ofDNMT3bwas upregu-
lated in all our pluripotent cells (Figure 1E). How HCpG
gene promoters are protected from the de novo methyl-
ation is yet not fully understood. Binding of proteins to
CpG islands may interfere with the DNMTs attempt to
methylate these HCpG promoters, but more work is
needed to show if this is indeed the case. Finally, several
recent works suggest that methylation plays a key role in
mediating the ability of cells to differentiate (Bar-NurStem Cell Ret al., 2011; Kim et al., 2010; Lister et al., 2011; Nagae
et al., 2011; Polo et al., 2010), sometime due to an epige-
netic memory (Bar-Nur et al., 2011; Kim et al., 2010; Lister
et al., 2011; Polo et al., 2010). We propose that a thorough
dissection of the methylation status of each iPSCs will
greatly benefit the use of iPSCs for direct differentiation
protocols and in using the cells for potential cell replace-
ment therapy.EXPERIMENTAL PROCEDURES
Generation and Culture of iPSCs
Generation of fibroblast iPSCs, beta iPSCs, and parthenogenetic
iPSCs were reported previously (Bar-Nur et al., 2011; Pick et al.,
2009; Stelzer et al., 2011). See the Supplemental Experimental Pro-
cedures for full culture conditions.
DNA and mRNA Extraction
Total genomicDNAwas extracted using a genomicDNA extraction
kit (RBC). Total RNA (DNase-treated) was extracted using the
RNAeasy Mini Kit (QIAGEN).
DNAExpression andMethylationMicroarrayAnalyses
RNA and DNAwere subjected to either HumanGene 1.0 STmicro-
array platform (Affymetrix) or to HumanMethylation27 BeadChip
(Illumina) analysis, respectively. See the Supplemental Experi-
mental Procedures for further details.
ACCESSION NUMBERS
Microarray expression data are available in the Gene Expression
Omnibus (GEO) database under the accession numbers
GSE27362 and GSE29880. Illumina methylation data have been
deposited in GEO under the accession number GSE52238.eports j Vol. 1 j 509–517 j December 17, 2013 j ª2013 The Authors 515
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Supplemental Information includes Supplemental Experimental
Procedures, two figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2013.11.007.
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